** U.S.-listed shares of drugmaker Aurinia Pharmaceuticals
up 6.6% at $7.01
** Tang Capital Management reports 5.1% stake in AUPH as of Sept. 6
** Separately, AUPH said on Thursday it has restructured its board and has allowed CEO Peter Greenleaf to continue as a director
** AUPH says Greenleaf had conditionally resigned as a director because he received less-than-majority support at the 2024 AGM
** Company's board says it has considered all relevant factors and determined there are exceptional circumstances that warrant the rejection of Greenleaf's conditional resignation
** AUPH says its board has appointed Kevin Tang, president of Tang Capital Management as a director
** Shareholder Lucien Selce, co-founder of Vista Capital Management, has been urging other investors in AUPH to remove the CEO
** Stock was down nearly 27% YTD
(Reporting by Ananya Mariam Rajesh in Bengaluru)
((AnanyaMariam.Rajesh@thomsonreuters.com ; X: ))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。